Skip to content
  • Home
  • Sales
    • 1st Quarter Sales
    • 2nd Quarter Sales
    • 3rd Quarter Sales
    • 4th Quarter Sales
  • Leases
  • Advertise
  • Subscribe
  • Login
  • Home
  • Sales
    • 1st Quarter Sales
    • 2nd Quarter Sales
    • 3rd Quarter Sales
    • 4th Quarter Sales
  • Leases
  • Advertise
  • Subscribe
  • Login

Eurofins CellTx Expands Services to Advance the Future of Cell and Tissue-Based Therapies

  • Home
  • News
  • Eurofins CellTx Expands Services to Advance the Future of Cell and Tissue-Based Therapies
News
/
October 1, 2026
/
Real Estate Daily News Service
image_pdfimage_print

Eurofins CellTx In just five years, what began as a specialized donor testing laboratory at the UA Tech Park has evolved into a globally recognized operation supporting cell and tissue-based innovations across six continents.

 TUCSON, Ariz. (Oct. 1, 2026) – Eurofins CellTx, LLC, a specialized testing laboratory located at the UA Tech Park, has expanded its service offerings to provide comprehensive quality and functional assessment of human cell and tissue products, positioning the company to support the next generation of regenerative medicine, biotherapies, and reproductive health applications worldwide.

Founded in 2021, Eurofins CellTx was established to focus on donor eligibility testing for living donor human cells, tissues, and cellular and tissue-based products, including stem cells, cord blood, bone marrow, reproductive cells, and perinatal tissues. In just five years, the Tucson-based operation, part of the global network of Eurofins laboratories, has grown into a state-of-the-art testing facility supporting organizations across six continents. Today, Eurofins CellTx combines scientific expertise, rapid turnaround times, and a commitment to quality through compliance with FDA, CLIA, ISO 15189, and current Good Manufacturing Practice (cGMP) standards.

As the company enters its fifth year of operations, Eurofins CellTx is expanding its mission to address a growing need within the cell and reproductive fertility industries: evaluating not only the safety of cell and tissue products, but also their quality, integrity, and functional performance. This evolution builds upon the laboratory's longstanding foundation in donor eligibility and safety testing while providing clients with deeper insights into the quality and functionality of cell and tissue products. The expanded capabilities are designed to support informed decision-making and ultimately contribute to improved patient outcomes.

This enhanced service portfolio supports a broader strategy designed to strengthen donor selection and source material evaluation for cell and biotherapies, as well as reproductive and fertility applications. By combining scientific expertise, rapid turnaround times, and regulatory excellence, Eurofins CellTx helps clients accelerate donor qualification, streamline processes, and minimize delays in product release and treatment.

The laboratory recently achieved cGMP accreditation, further demonstrating its commitment to quality, consistency, and patient safety. The accreditation reflects the implementation of rigorous systems, controls, documentation, and oversight designed to ensure reliable and reproducible testing services while meeting regulatory expectations for clinical and commercial programs. As advanced therapies continue to transform healthcare, these quality systems provide an important foundation for organizations developing innovative treatments and bringing them to patients worldwide.

The company's name itself reflects that mission. While "Cell" represents the laboratory's focus on human cell and tissue products, "Tx" symbolizes the ultimate purpose of those donations and therapies. Whether through transplantation, treatment, therapy, transfer, or transfusion, Eurofins CellTx supports the critical pathway that enables donated cells and tissues to reach patients in need.

Located within the UA Tech Park's innovation ecosystem, Eurofins CellTx continues to play an important role in supporting the rapidly growing life sciences sector in Southern Arizona while serving clients and healthcare innovators across the globe. Through continued collaboration with industry partners, researchers and healthcare professionals, the company is expanding its capabilities to support the development of safe, high-quality therapies that have the potential to improve lives across the globe.

Share Now!

Recent Posts

  • Shallow Bay Industrial Portfolio Sold in Tucson for $165.75 Million
  • $47.8 Million Multifamily Asset Sale in Midtown Phoenix Brokered by Institutional Property Advisors
  • Eurofins CellTx Expands Services to Advance the Future of Cell and Tissue-Based Therapies
  • Stellar Steel Acquires Tucson’s Horizon Steel Property for $5.3 Million as Company Expands
  • Marcus & Millichap Arranges $3.45 Million Sale of Sunrise Schools Property in Tolleson

Archives

Copyright © 2026 Real Estate Daily News
Website by: Heart and Soul Web Design

Scroll to Top